Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs Waste Management, Inc. (WM) Price & Performance

Inovio Pharmaceuticals IncTrade
Waste Management, Inc.Trade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs Waste Management, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $0.8 (market cap $78.55M), while Waste Management, Inc. trades at $226.84 (market cap $90.68B). The key difference: Waste Management, Inc. is far larger — about 1154.4× Inovio Pharmaceuticals Inc's market cap, and Waste Management, Inc. pays a 1.56% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

INOWM
Market Cap
$78.55M$90.68B
Sector
HealthIndustrials
52-Week High
$2.87$246.51
52-Week Low
$0.66$196.77
Enterprise Value
$49.56M$113.47B
Dividend Yield
1.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.

Waste Management, Inc.

WM trades at $226.19, down 0.18% today, with a neutral technical signal and strong fundamentals. Recent Q2 2026 earnings beat estimates at $2.02 per share, driven by pricing discipline and margin gains. Revenue growth is steady, with 2025 revenue at $25.20 billion, though net income margin dipped to 10.74%. The stock shows a bullish analyst consensus with a $263.43 price target, supported by 20 buy ratings and no sell recommendations. Institutional activity includes mixed trades, such as Bank of America reducing holdings by 6.1% in Q1 2026 (SEC filing, 2026-08-01).

Outlook remains positive due to consistent earnings beats and operational efficiency, but risks include high valuation ratios like a P/E of 59.74 and rising debt levels, with total liabilities at $36.31 billion in 2024. Investors should weigh growth potential against margin pressures and macroeconomic headwinds affecting waste volumes.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO

About Waste Management, Inc.

Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.

Read more on WM